{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:18:53Z","timestamp":1765354733346,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T00:00:00Z","timestamp":1602288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA021765"],"award-info":[{"award-number":["P30 CA021765"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00280-020-04160-7","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T15:03:00Z","timestamp":1602342180000},"page":"711-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6549","authenticated-orcid":false,"given":"Senthil Velan","family":"Bhoopalan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane J.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Panetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon M.","family":"Triplett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,10]]},"reference":[{"issue":"19","key":"4160_CR1","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/cncr.30791","volume":"123","author":"TB Alexander","year":"2017","unstructured":"Alexander TB, Wang L, Inaba H, Triplett BM, Pounds S, Ribeiro RC, Pui CH, Rubnitz JE (2017) Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer 123(19):3791\u20133798. https:\/\/doi.org\/10.1002\/cncr.30791","journal-title":"Cancer"},{"issue":"14","key":"4160_CR2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","volume":"129","author":"D Campana","year":"2017","unstructured":"Campana D, Pui C-H (2017) Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood 129(14):1913\u20131918. https:\/\/doi.org\/10.1182\/blood-2016-12-725804","journal-title":"Blood"},{"issue":"2","key":"4160_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MOH.0000000000000412","volume":"25","author":"JH Liu","year":"2018","unstructured":"Liu JH, Kanakry CG, Luznik L (2018) Have haploidentical transplants replaced umbilical cord transplants for acute leukemias? Curr Opin Hematol 25(2):103\u2013111","journal-title":"Curr Opin Hematol"},{"key":"4160_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines5020033","author":"J Vadakekolathu","year":"2017","unstructured":"Vadakekolathu J, Rutella S (2017) T-cell manipulation strategies to prevent graft-versus-host disease in haploidentical stem cell transplantation. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines5020033","journal-title":"Biomedicines"},{"issue":"7","key":"4160_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1182\/blood-2013-10-531764","volume":"123","author":"MF Martelli","year":"2014","unstructured":"Martelli MF, Di Ianni M, Ruggeri L, Pierini A, Falzetti F, Carotti A, Terenzi A, Reisner Y, Aversa F, Falini B, Velardi A (2014) \"Designed\" grafts for HLA-haploidentical stem cell transplantation. Blood 123(7):967\u2013973. https:\/\/doi.org\/10.1182\/blood-2013-10-531764","journal-title":"Blood"},{"issue":"6","key":"4160_CR6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/j.1365-2141.2008.07557.x","volume":"144","author":"JG Gribben","year":"2009","unstructured":"Gribben JG, Hallek M (2009) Rediscovering alemtuzumab: current and emerging therapeutic roles. Br J Haematol 144(6):818\u2013831. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07557.x","journal-title":"Br J Haematol"},{"issue":"7","key":"4160_CR7","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96(7):2419\u20132425","journal-title":"Blood"},{"issue":"1","key":"4160_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/bmt.2013.132","volume":"49","author":"A Marek","year":"2014","unstructured":"Marek A, Stern M, Chalandon Y, Ansari M, Ozsahin H, Gungor T, Gerber B, Kuhne T, Passweg JR, Gratwohl A, Tichelli A, Seger R, Schanz U, Halter J, Stussi G, Swiss Blood Stem Cell T (2014) The impact of T-cell depletion techniques on the outcome after haploidentical hematopoietic SCT. Bone Marrow Transplant 49(1):55\u201361. https:\/\/doi.org\/10.1038\/bmt.2013.132","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4160_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2125.2007.02914.x","volume":"64","author":"DR Mould","year":"2007","unstructured":"Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL (2007) Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 64(3):278\u2013291. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02914.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"4160_CR10","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40262-019-00782-0","volume":"58","author":"R Admiraal","year":"2019","unstructured":"Admiraal R, Jol-van der Zijde CM, Furtado Silva JM, Knibbe CAJ, Lankester AC, Boelens JJ, Hale G, Etuk A, Wilson M, Adams S, Veys P, van Kesteren C, Bredius RGM (2019) Population pharmacokinetics of alemtuzumab (campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome. Clin Pharmacokinet 58(12):1609\u20131620. https:\/\/doi.org\/10.1007\/s40262-019-00782-0","journal-title":"Clin Pharmacokinet"},{"key":"4160_CR11","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3389\/fimmu.2019.02769","volume":"10","author":"F Aversa","year":"2019","unstructured":"Aversa F, Pierini A, Ruggeri L, Martelli MF, Velardi A (2019) The evolution of T cell depleted haploidentical transplantation. Front Immunol 10:2769. https:\/\/doi.org\/10.3389\/fimmu.2019.02769","journal-title":"Front Immunol"},{"issue":"5","key":"4160_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481\u2013504","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"23","key":"4160_CR13","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","volume":"128","author":"R Admiraal","year":"2016","unstructured":"Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, Boelens JJ (2016) Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood 128(23):2734\u20132741. https:\/\/doi.org\/10.1182\/blood-2016-06-721936","journal-title":"Blood"},{"issue":"11","key":"4160_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/ajh.24141","volume":"90","author":"H Abdel-Azim","year":"2015","unstructured":"Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM, Shah AJ, Kapoor N (2015) Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: an alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. Am J Hematol 90(11):1021\u20131026. https:\/\/doi.org\/10.1002\/ajh.24141","journal-title":"Am J Hematol"},{"issue":"4","key":"4160_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","volume":"127","author":"RA Marsh","year":"2016","unstructured":"Marsh RA, Lane A, Mehta PA, Neumeier L, Jodele S, Davies SM, Filipovich AH (2016) Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT. Blood 127(4):503\u2013512. https:\/\/doi.org\/10.1182\/blood-2015-07-659672","journal-title":"Blood"},{"issue":"3","key":"4160_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.bbmt.2014.11.005","volume":"21","author":"KM Mahadeo","year":"2015","unstructured":"Mahadeo KM, Weinberg KI, Abdel-Azim H, Miklos DB, Killen R, Kohn D, Crooks GM, Shah AJ, Kharbanda S, Agarwal R, Kapoor N (2015) A reduced-toxicity regimen is associated with durable engraftment and clinical cure of nonmalignant genetic diseases among children undergoing blood and marrow transplantation with an HLA-matched related donor. Biol Blood Marrow Transplant 21(3):440\u2013444. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"4160_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/146532401317070899","volume":"3","author":"P Rebello","year":"2001","unstructured":"Rebello P, Cwynarski K, Varughese M, Eades A, Apperley JF, Hale G (2001) Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3(4):261\u2013267. https:\/\/doi.org\/10.1080\/146532401317070899","journal-title":"Cytotherapy"},{"issue":"10","key":"4160_CR18","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/bmt.2010.308","volume":"46","author":"A Spyridonidis","year":"2011","unstructured":"Spyridonidis A, Liga M, Triantafyllou E, Themeli M, Marangos M, Karakantza M, Zoumbos N (2011) Pharmacokinetics and clinical activity of very low-dose alemtuzumab in transplantation for acute leukemia. Bone Marrow Transplant 46(10):1363\u20131368. https:\/\/doi.org\/10.1038\/bmt.2010.308","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"4160_CR19","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/ajh.20694","volume":"81","author":"K Oshima","year":"2006","unstructured":"Oshima K, Kanda Y, Nakahara F, Shoda E, Suzuki T, Imai Y, Watanabe T, Asai T, Izutsu K, Ogawa S, Motokura T, Chiba S, Kurokawa M (2006) Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies. Am J Hematol 81(11):875\u2013879. https:\/\/doi.org\/10.1002\/ajh.20694","journal-title":"Am J Hematol"},{"issue":"3","key":"4160_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/ejh.13204","volume":"102","author":"S Kako","year":"2019","unstructured":"Kako S, Gomyo A, Akahoshi Y, Harada N, Kameda K, Ugai T, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Sato M, Terasako-Saito K, Kimura S-I, Kikuchi M, Nakasone H, Kanda J, Kanda Y (2019) Haploidentical transplantation using low-dose alemtuzumab: comparison with haploidentical transplantation using low-dose thymoglobulin. Eur J Haematol 102(3):256\u2013264. https:\/\/doi.org\/10.1111\/ejh.13204","journal-title":"Eur J Haematol"},{"issue":"3","key":"4160_CR21","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/j.bbmt.2015.11.438","volume":"22","author":"R Admiraal","year":"2016","unstructured":"Admiraal R, van Kesteren C, Nierkens S, Boelens J-J, Lacna AM, Ebskamp-van Raaij L (2016) Individualized dosing and therapeutic drug monitoring for anti-thymocyte globulin to improve outcome following cord blood transplantation: proof of concept. Biol Blood Marrow Transplant 22(3):S116","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4160_CR22","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.bbmt.2017.01.046","volume":"23","author":"CA Lindemans","year":"2017","unstructured":"Lindemans CA, Admiraal R, Haar CG, van Raaij LEE, Lacna AM, Bierings M, Nierkens S, Boelens J-J (2017) Individualized dosing and therapeutic drug monitoring (TDM) of ATG is feasible, safe, effective, and associated with excellent immune reconstitution. Biol Blood Marrow Transplant 23(3):S124\u2013S125","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04160-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04160-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:11:28Z","timestamp":1633911088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04160-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,10]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4160"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04160-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2020,10,10]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"B.M.T. received travel support for EBMT 2018 Annual Meeting from Miltenyi Biotec Inc to present published data. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was approved by IRB and Ethics Committee of our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent obtained from patients and\/or parents.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent obtained from patients and\/or parents.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}